Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > This stock has dropped the whole year

<< Previous

Bullboard Posts

Next >>

Comment by Ryeman40on Dec 20, 2020 3:18am

186 Views

Post# 32148527

RE:RE:RE:This stock has dropped the whole year

Lol. Ok you said it never doubled at ALL and i just proved you wrong. Now you are changing the narrative. Antibe is trading where it's suppose to be at because it's a speculative bio and this is the space they trade in and if you didn't know that you shouldn't be trading bio's. Now's the time to buy. Close to the bottom with some major catalyst's coming up.

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China